Abstract Submission Deadline 

1 October 2021

GUIDELINES FOR AUTHORS

The submitted abstracts must be written exclusively in English. The presentations and oral posters content will also be in English.

➣  The size of the abstract is limited to 2500 characters and must not contain images, tables or graphics.
➣  Within the title and the body text of the abstract, identifying details such as the names of authors or hospitals should not be mentioned, so that anonymous review can be done.
➣ The use of commercial drug names, brands and registered trademarks are strictly prohibited and no mention of pharmaceutical company names should be included in the abstract. Drugs should be referred to by the active substance or pharmacological designation.
➣  Abstract editing will be possible until the submission deadline.
➣ The submitted abstracts will adhere to the following structure: Title, Authors, Objectives, Materials and methods, Results, Conclusions, Keywords.

➣  The maximum number of authors is limited to 6.
➣  The presenting author will not mandatory be the main author as well.
➣ The presenting author will receive abstract related information and must be registered as congress participant by the 10th of September 2021.

The abstracts will be evaluated through the blind review process, taking into consideration the following criteria: the relevance of the topic, the clinical usefulness, originality, appropriate abstract structure (stating a precise Objective, a clear and reproducible Methodology, concise description of the Results and a clear Conclusion supported by study results), research methodology, analysis methodology, reliability of the supporting evidence and, of course, grammar and spelling.

 Submission of previously published or presented abstracts in other congresses is forbidden.

Within the peer review process, all submitted abstracts will be filtered through a dedicated Anti-Plagiarism software. In cases with potential plagiarism, if less than 30% of the original submission is plagiarized, a notification will be sent to the authors about the issues, to either rewrite the part, or cite the original author. The abstracts detected with more than 30% of the original submission as plagiarized, will be automatically rejected.